Eloxx Pharmaceuticals Ltd, a clinical stage company developing therapeutics for genetic diseases caused by non-sense mutations, has secured an addition $6 million to close its Series C round at $30 million.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
